Back to search results

Study of Secretin (Chirostim) for Pancreatic Fluid in Healthy Subjects

This study is looking at how a medicine called Secretin (human synthetic), also known as ChiRhoStim, affects the fluid produced by your pancreas. Researchers will give you a dose of Secretin through an IV during an endoscopic ultrasound (EUS), which is a procedure where a thin, flexible tube with a camera and ultrasound probe is inserted into your digestive tract. They will then collect small samples of pancreatic fluid from your small intestine at different times to measure the levels of bicarbonate, sodium, and potassium. This study aims to understand the normal composition of pancreatic fluid after stimulation. You may be able to join if you are between 18 and 80 years old, in good health, and are already having an EUS for a reason not related to your pancreas. The study plans to enroll 24 healthy individuals.

Study design
This is an interventional study with 24 planned participants. It is not specified if it is randomized or blinded.
What's involved
You would receive an intravenous dose of Secretin during an endoscopic ultrasound. Pancreatic fluid samples would be collected at 5, 10, 15, and 20 minutes after the Secretin is given.
Compensation
Not stated in the trial record.
Follow-up
Pancreatic fluid composition is measured up to 20 minutes after Secretin administration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07285863

A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects

Recruiting
PHASE4Ages 18–80Interventional
Mayo Clinic
~24 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:Secretin (human synthetic) - ChiRhoClin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pancreatic Fluid Bicarbonate Composition
Measured over 5, 10, 15, and 20-minutes post-secretin administration
+3 more outcomes measured

Conditions

Exocrine Pancreatic Insufficiency
Chronic Pancreatitis

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Samuel Han, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Liz Lemke
[email protected]
507-266-3317
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Males or non-pregnant females
Age 18-80.
Participants must be in good health based on medical history (ASA Class 3 or below)
Participants must be willing and able to provide informed consent
Receiving an endoscopic ultrasound for a non-pancreatic indication

Exclusion

History of any form of pancreatitis and/or other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses).
History of inflammatory bowel disease
History of vagotomy.
History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I/II)
History of liver disease
Pregnant women or nursing mothers
Regular use of anticholinergics
\> 2 drinks of alcohol daily
Smokers (cigarette)

What this trial measures

  • Pancreatic Fluid Bicarbonate Composition5, 10, 15, and 20-minutes post-secretin administration

    A primary outcome will be the bicarbonate level (milliequivalent per liter) in the pancreatic fluid collected.

  • Pancreatic Fluid Sodium Composition5, 10, 15, and 20-minutes post-secretin administration

    A primary outcome will be the sodium level (milliequivalent per liter) in the pancreatic fluid collected.

  • Pancreatic Fluid Potassium Composition5, 10, 15, and 20-minutes post-secretin administration

    A primary outcome will be the potassium level (milliequivalent per liter) in the pancreatic fluid collected.

  • Pancreatic Fluid Chloride Composition5, 10, 15, and 20-minutes post-secretin administration

    A primary outcome will be the chloride level (milliequivalent per liter) in the pancreatic fluid collected.